Drug Profile
Disitamab vedotin - Yantai Rongchang Pharmaceutical
Alternative Names: Aidixi; RC 48; RC 48-ADC; Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate - Yantai Rongchang PharmaceuticalLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Yantai Rongchang Biological Engineering
- Developer RemeGen; Seagen
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastric cancer
- Registered Urogenital cancer
- Phase III HER2 positive breast cancer
- Phase II Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Gynaecological cancer; Malignant melanoma; Solid tumours
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 10 Mar 2024 Efficacy and adverse events data from phase-II trial in Gynaecological cancer (Monotherapy) presented at the European Congress on Gynaecological Oncology (ESGO -2024 Congress)
- 07 Feb 2024 Seagen initiates a phase Ib/II trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06157892)
- 02 Feb 2024 Efficacy and adverse event data from a Phase II/III trial for Gastric cancer released by RemeGen